Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

AbbVie Announces Updated Results From Phase 2 EPCOREÂź NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

(NYSE:ABBV) Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from ...

Symbol: ABBV
about 14 hours ago